HRP20190689T1 - Muteini suznog lipokalina koji vežu il-4r alfa - Google Patents
Muteini suznog lipokalina koji vežu il-4r alfa Download PDFInfo
- Publication number
- HRP20190689T1 HRP20190689T1 HRP20190689TT HRP20190689T HRP20190689T1 HR P20190689 T1 HRP20190689 T1 HR P20190689T1 HR P20190689T T HRP20190689T T HR P20190689TT HR P20190689 T HRP20190689 T HR P20190689T HR P20190689 T1 HRP20190689 T1 HR P20190689T1
- Authority
- HR
- Croatia
- Prior art keywords
- glu
- arg
- leu
- ala
- ser
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35246110P | 2010-06-08 | 2010-06-08 | |
| EP11726380.6A EP2580236B1 (en) | 2010-06-08 | 2011-06-08 | Tear lipocalin muteins binding il-4 r alpha |
| PCT/EP2011/059420 WO2011154420A2 (en) | 2010-06-08 | 2011-06-08 | Tear lipocalin muteins binding il-4 r alpha |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190689T1 true HRP20190689T1 (hr) | 2019-06-14 |
Family
ID=44627297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190689TT HRP20190689T1 (hr) | 2010-06-08 | 2011-06-08 | Muteini suznog lipokalina koji vežu il-4r alfa |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US8986951B2 (https=) |
| EP (1) | EP2580236B1 (https=) |
| JP (3) | JP5902679B2 (https=) |
| CN (3) | CN103038249B (https=) |
| AU (1) | AU2011263786B2 (https=) |
| CA (1) | CA2800026C (https=) |
| CY (1) | CY1122339T1 (https=) |
| DK (1) | DK2580236T3 (https=) |
| ES (1) | ES2729652T3 (https=) |
| HR (1) | HRP20190689T1 (https=) |
| HU (1) | HUE043835T2 (https=) |
| LT (1) | LT2580236T (https=) |
| NZ (1) | NZ603562A (https=) |
| PL (1) | PL2580236T3 (https=) |
| PT (1) | PT2580236T (https=) |
| RS (1) | RS58839B1 (https=) |
| RU (1) | RU2569745C2 (https=) |
| SG (1) | SG186161A1 (https=) |
| SI (1) | SI2580236T1 (https=) |
| SM (1) | SMT201900297T1 (https=) |
| TR (1) | TR201906295T4 (https=) |
| WO (1) | WO2011154420A2 (https=) |
| ZA (1) | ZA201209160B (https=) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9829494B2 (en) | 2005-12-01 | 2017-11-28 | Adrenomed Ag | Methods of treatment using ADM antibodies |
| RU2569745C2 (ru) * | 2010-06-08 | 2015-11-27 | Пиерис АГ | Мутеины липокалина слезы, связывающие альфа il-4 r |
| PL2594588T3 (pl) | 2011-11-16 | 2014-11-28 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii |
| SG11201402362VA (en) | 2011-11-16 | 2014-06-27 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| EP2780370B1 (en) | 2011-11-16 | 2019-09-25 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| EP4086283A1 (en) | 2011-11-16 | 2022-11-09 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
| DK2780371T3 (en) | 2011-11-16 | 2019-02-25 | Adrenomed Ag | ANTI-ADDRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTISTOFFRAGMENT OR ANTI-ADM NON-IG TEMPLATE FOR REGULATING LIQUID BALANCE OF A PATIENT WITH A CHRONIC OR ACUTE DISEASE |
| DK2780717T3 (en) | 2011-11-16 | 2017-02-13 | Sphingotec Gmbh | ADRENOMEDULLINASSAYS AND METHODS FOR DETERMINING MODERN ADRENOMEDULLIN |
| ES2710384T3 (es) | 2011-12-13 | 2019-04-24 | Pieris Pharmaceuticals Gmbh | Procedimientos para la prevención o el tratamiento de determinados trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores |
| CN103308673B (zh) | 2012-03-08 | 2017-05-31 | 思芬构技术有限公司 | 用于预测雌性对象中发生心血管事件的风险的方法 |
| CN103308670B (zh) | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
| CN103308689B (zh) | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
| WO2013174783A1 (en) * | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| TR201809001T4 (tr) | 2012-10-02 | 2018-07-23 | Sphingotec Gmbh | Böbrek fonksiyonunu teşhis etmek veya izlemek veya böbrek fonksiyonu bozukluğunu teşhis etmek için bir usul. |
| WO2014076321A1 (en) * | 2012-11-19 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| CA2897327A1 (en) | 2013-01-08 | 2014-07-17 | Sphingotec Gmbh | Fasting levels of growth hormone as a predictive marker of cardiovascular risk |
| HK1213194A1 (zh) * | 2013-03-14 | 2016-06-30 | Daiichi Sankyo Co., Ltd. | 用於新型的结合蛋白质pcsk9 |
| EP2976646B1 (en) | 2013-03-20 | 2020-08-19 | sphingotec GmbH | Adrenomedullin to guide therapy of blood pressure decline |
| SG11201609274SA (en) | 2014-05-22 | 2016-12-29 | Pieris Pharmaceuticals Gmbh | Novel specific-binding polypeptides and uses thereof |
| EP3002589A1 (en) | 2014-10-01 | 2016-04-06 | sphingotec GmbH | A method for stratifying a female subject for hormone replacement therapy |
| US11382963B2 (en) * | 2015-01-12 | 2022-07-12 | Pieris Pharmaceuticals Gmbh | Engineered T cells and uses therefor |
| RU2733471C2 (ru) | 2015-04-24 | 2020-10-01 | Сфинготек Гмбх | Способ прогнозирования риска развития хронического заболевания почек |
| AU2016262838B2 (en) | 2015-05-18 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3) |
| TW201725212A (zh) * | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| AU2017252212B2 (en) | 2016-04-21 | 2023-09-07 | 4TEEN4 Pharmaceuticals GmbH | Methods for determining DPP3 and therapeutic methods |
| US11390661B2 (en) | 2016-06-27 | 2022-07-19 | Aicuris Anti-Infective Cures Gmbh | HCMV entry inhibitors |
| EP4231018A3 (en) | 2016-07-08 | 2023-11-15 | SphingoTec GmbH | Adrenomedullin for assessing congestion in a subject with acute heart failure |
| EP3309550A1 (en) | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| KR20240033285A (ko) | 2016-12-16 | 2024-03-12 | 아드레노메드 아게 | 울혈의 중재 및 치료가 필요한 환자에서 울혈의 중재 및 치료에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드 |
| EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| BR112019024966A2 (pt) | 2017-05-30 | 2020-06-23 | Sphingotec Gmbh | Método para diagnosticar ou monitorar a função renal ou diagnosticar a disfunção renal |
| FI3687567T3 (fi) | 2017-09-25 | 2025-01-08 | Adrenomed Ag | Adrenomedulliinin (adm) vasta-ainetta sitova aine käytettäväksi sairauden oireiden hoidossa tai ehkäisyssä |
| SG11202002268XA (en) | 2017-10-18 | 2020-04-29 | Adrenomed Ag | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder |
| MX2020004219A (es) | 2017-10-24 | 2020-07-22 | Sphingotec Gmbh | Selenoproteina p para prediccion de un primer evento cardiovascular. |
| MY202502A (en) | 2017-10-25 | 2024-05-01 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress |
| US20210302440A1 (en) | 2018-02-08 | 2021-09-30 | Sphingotec Gmbh | Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia |
| EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
| EP3586865A1 (en) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
| BR112021010069A2 (pt) | 2018-12-20 | 2021-11-23 | Sphingotec Gmbh | Selenoproteína p em insuficiência cardíaca |
| WO2020128039A2 (en) | 2018-12-21 | 2020-06-25 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof |
| AU2020253034A1 (en) | 2019-03-29 | 2021-08-19 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| US20220193191A1 (en) | 2019-03-29 | 2022-06-23 | Astrazeneca Ab | Lipocalin mutein for treatment of asthma |
| CN114364984A (zh) | 2019-08-15 | 2022-04-15 | 思芬构技术有限公司 | 一种诊断或监测儿科患者的肾功能或诊断肾功能障碍的方法 |
| BR112022002856A2 (pt) | 2019-08-30 | 2022-08-09 | 4TEEN4 Pharmaceuticals GmbH | Orientação de terapia e/ou monitoramento de terapia para o tratamento de choque |
| US11231198B2 (en) | 2019-09-05 | 2022-01-25 | Trane International Inc. | Systems and methods for refrigerant leak detection in a climate control system |
| EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| CN115244401A (zh) | 2020-02-27 | 2022-10-25 | 4Teen4制药有限公司 | 用于在休克患者中进行nt-adm抗体的治疗指导、监测和分层的dpp3 |
| CA3168978A1 (en) | 2020-02-27 | 2021-09-02 | Andreas Bergmann | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| MX2022010564A (es) | 2020-02-27 | 2022-11-30 | Adrenomed Ag | Aglutinante anti-adrenomedulina (adm) para usarse en terapia de pacientes en choque. |
| US20210285949A1 (en) | 2020-03-16 | 2021-09-16 | Sphingotec Gmbh | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
| EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| WO2021185786A1 (en) | 2020-03-16 | 2021-09-23 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| EP4023218A1 (en) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
| KR20230121785A (ko) | 2020-12-18 | 2023-08-21 | 아스트라제네카 에이비이 | 천식 치료용 리포칼린 뮤테인 건조 분말 제형 |
| WO2022263648A1 (en) | 2021-06-18 | 2022-12-22 | Sphingotec Gmbh | A method for predicting sepsis and septic shock |
| WO2023275099A1 (en) | 2021-06-29 | 2023-01-05 | Berysol Gmbh | Composite biomarker for the identification of selenium deficiency in a bodily fluid |
| CN113943374B (zh) * | 2021-09-24 | 2024-04-30 | 广东菲鹏制药股份有限公司 | 一种白介素15及其受体的多肽复合物 |
| CA3254142A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | STABLE AQUEOUS FORMULATION OF AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADM ANTIBODY FRAGMENT |
| CN119630969A (zh) | 2022-07-29 | 2025-03-14 | 4Teen4制药有限公司 | 预测患有败血症性休克的患者中的dpp3增加 |
| KR20250042158A (ko) | 2022-07-29 | 2025-03-26 | 아드레노메드 아게 | 쇼크의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드 |
| CN120359042A (zh) | 2022-12-15 | 2025-07-22 | 4Teen4制药有限公司 | 改善危重病患者肺功能的dpp3抑制剂 |
| CN120731367A (zh) | 2023-03-17 | 2025-09-30 | Pam治疗诊断有限公司 | 肽基甘氨酸α-酰胺化单加氧酶（PAM）的测定方法及其诊断用途 |
| WO2024200862A1 (en) | 2023-03-29 | 2024-10-03 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline |
| WO2025068313A1 (en) | 2023-09-25 | 2025-04-03 | Sphingotec Gmbh | A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient |
| WO2025229075A1 (en) | 2024-05-03 | 2025-11-06 | Sphingotec Gmbh | A method for the specific determination of proenkephalin fragment 119-159 |
| WO2025248139A1 (en) | 2024-05-31 | 2025-12-04 | 4TEEN4 Pharmaceuticals GmbH | Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof |
| EP4675277A1 (en) | 2024-07-05 | 2026-01-07 | Predemtec AG | A method for diagnosing alzheimer´s disease or determining the risk of suffering from alzheimer´s disease |
| WO2026046968A1 (en) | 2024-08-26 | 2026-03-05 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 binders for the treatment of endothelial dysfunction |
| WO2026046978A1 (en) | 2024-08-26 | 2026-03-05 | Pam Theragnostics Gmbh | Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| US6446467B1 (en) | 1997-07-29 | 2002-09-10 | Physical Optics Corporation | Monolithic glass light shaping diffuser and method for its production |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| CZ298681B6 (cs) | 1998-06-08 | 2007-12-19 | F. Hoffmann-La Roche Ag | Lécivo pro lécení infekcí chronické hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| CA2464690A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| US7238661B2 (en) | 2002-05-24 | 2007-07-03 | Agennix, Inc. | Oral lactoferrin in the treatment of respiratory disorders |
| WO2005019255A1 (en) * | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| RU2389796C2 (ru) * | 2003-08-29 | 2010-05-20 | Аэровэнс, Инк. | Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид |
| US7404957B2 (en) | 2003-08-29 | 2008-07-29 | Aerovance, Inc. | Modified IL-4 mutein receptor antagonists |
| WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
| EP1929073A4 (en) | 2005-09-27 | 2010-03-10 | Amunix Inc | PROTEIN MEDICAMENT AND ITS USE |
| WO2007107563A2 (en) | 2006-03-20 | 2007-09-27 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| US8313924B2 (en) * | 2006-08-01 | 2012-11-20 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| CN101516907B (zh) * | 2006-08-01 | 2015-08-26 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
| EP2178547A4 (en) | 2007-07-11 | 2011-02-16 | Aerovance Inc | PHARMACEUTICAL POLYPEPTIDE DRY POWDER AEROSOL FORMULATION AND MANUFACTURING METHOD |
| RU2569745C2 (ru) * | 2010-06-08 | 2015-11-27 | Пиерис АГ | Мутеины липокалина слезы, связывающие альфа il-4 r |
| ES2710384T3 (es) * | 2011-12-13 | 2019-04-24 | Pieris Pharmaceuticals Gmbh | Procedimientos para la prevención o el tratamiento de determinados trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores |
-
2011
- 2011-06-08 RU RU2012150766/15A patent/RU2569745C2/ru active
- 2011-06-08 JP JP2013513670A patent/JP5902679B2/ja not_active Expired - Fee Related
- 2011-06-08 EP EP11726380.6A patent/EP2580236B1/en active Active
- 2011-06-08 PT PT11726380T patent/PT2580236T/pt unknown
- 2011-06-08 SG SG2012089116A patent/SG186161A1/en unknown
- 2011-06-08 CN CN201180028367.9A patent/CN103038249B/zh not_active Expired - Fee Related
- 2011-06-08 SI SI201131711T patent/SI2580236T1/sl unknown
- 2011-06-08 CN CN201610143597.4A patent/CN105949301B/zh not_active Expired - Fee Related
- 2011-06-08 SM SM20190297T patent/SMT201900297T1/it unknown
- 2011-06-08 PL PL11726380T patent/PL2580236T3/pl unknown
- 2011-06-08 DK DK11726380.6T patent/DK2580236T3/da active
- 2011-06-08 AU AU2011263786A patent/AU2011263786B2/en not_active Ceased
- 2011-06-08 CN CN202010135181.4A patent/CN111499725A/zh active Pending
- 2011-06-08 CA CA2800026A patent/CA2800026C/en active Active
- 2011-06-08 LT LTEP11726380.6T patent/LT2580236T/lt unknown
- 2011-06-08 WO PCT/EP2011/059420 patent/WO2011154420A2/en not_active Ceased
- 2011-06-08 NZ NZ603562A patent/NZ603562A/en not_active IP Right Cessation
- 2011-06-08 ES ES11726380T patent/ES2729652T3/es active Active
- 2011-06-08 HU HUE11726380A patent/HUE043835T2/hu unknown
- 2011-06-08 RS RS20190510A patent/RS58839B1/sr unknown
- 2011-06-08 US US13/702,792 patent/US8986951B2/en active Active
- 2011-06-08 TR TR2019/06295T patent/TR201906295T4/tr unknown
- 2011-06-08 HR HRP20190689TT patent/HRP20190689T1/hr unknown
-
2012
- 2012-12-05 ZA ZA2012/09160A patent/ZA201209160B/en unknown
-
2015
- 2015-03-23 US US14/665,692 patent/US9687524B2/en not_active Expired - Fee Related
- 2015-11-06 JP JP2015218174A patent/JP2016028604A/ja active Pending
-
2017
- 2017-06-05 US US15/613,958 patent/US10232014B2/en active Active
-
2019
- 2019-01-24 US US16/256,331 patent/US10898545B2/en not_active Expired - Fee Related
- 2019-01-30 JP JP2019014631A patent/JP6766194B2/ja not_active Expired - Fee Related
- 2019-06-06 CY CY20191100604T patent/CY1122339T1/el unknown
-
2020
- 2020-12-16 US US17/124,141 patent/US20210196788A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190689T1 (hr) | Muteini suznog lipokalina koji vežu il-4r alfa | |
| ME03709B (me) | Fuzijski proteini | |
| HRP20200871T1 (hr) | Izmjenjeni rsv f proteini i postupci njihove uporabe | |
| AU2014340241B2 (en) | Mutated fibroblast growth factor (FGF) 1 and methods of use | |
| JP2013537400A5 (https=) | ||
| IL278014B2 (en) | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use | |
| ATE517118T1 (de) | Bis-met-histone | |
| RU2017135605A (ru) | Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3) | |
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| JP2015504052A5 (https=) | ||
| NZ602634A (en) | Vista regulatory t cell mediator protein, vista binding agents and use thereof | |
| SI2797950T1 (en) | Fusion protein against cancer | |
| HRP20200428T1 (hr) | Sastavi alfa-galaktozidaze | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| RU2009128979A (ru) | Hla*1101-ограниченный пептид wt1 и содержащая его фармацевтическая композиция | |
| JP2013518115A5 (https=) | ||
| RU2017135599A (ru) | Белки, специфичные в отношении cd137 | |
| HRP20240135T1 (hr) | Fgf21 mutanti i njihove upotrebe | |
| CL2011003121A1 (es) | Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso. | |
| JP2018510622A5 (https=) | ||
| NZ606584A (en) | Binding proteins for hepcidin | |
| JP2010536333A5 (https=) | ||
| JP2013515055A5 (https=) | ||
| JP2018519802A5 (https=) | ||
| CA2752286A1 (en) | Humanized anti-cd20 antibodies and methods of use |